Nuvo Aiming For Fourth Quarter Response To Pennsaid “Approvable” Letter
This article was originally published in The Pink Sheet Daily
Already agreed-upon studies should be concluded in time, but FDA could require more animal data for approval of the topical NSAID.
You may also be interested in...
Canadian firm says new Phase III studies will not be necessary for the “approvable” NSAID lotion.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.